NTS Ventures and IHMA Announce a Significant and Important Program Focusing on Antifungal Resistance Surveillance: STAR (Susceptibility Trends in Antifungal Resistance)
SCHAUMBURG, Ill., June 12, 2019 (GLOBE NEWSWIRE) -- NTS Ventures (NTS), a mycology and antifungal clinical research laboratory and International Health Management Associates, Inc./IHMA Europe Sàrl (IHMA), a full-service central anti-infective clinical microbiology laboratory have announced a collaborative agreement that will provide the pharmaceutical industry with a brand-new antifungal resistance surveillance program termed STAR. In addition to the expertise provided by NTS and IHMA, STAR is heavily supported through affiliations with key opinion leader (KOL) laboratories throughout the world. As antifungal resistance rises and epidemiology changes, STAR will intimately monitor fluctuations and trends in antifungal resistance and epidemiology over time. It will be an excellent tool to serve authorities, biotechnology and pharmaceutical companies in the relentless fight against antifungal drug resistance. The clinical isolates prospectively collected through STAR will include all major yeasts (including the emerging pathogen Candida auris) and filamentous fungi, such as Aspergillus spp. as well as the rarer and highly invasive mold species such as Mucor spp., Rhizopus spp., among others.
The development of new antifungal agents is increasing. Consequently, STAR will support these drugs to ensure the fight against antifungal resistance will be more efficient and to gain precious time in reducing and eventually eliminating new resistance. The agreement between NTS and IHMA will allow all pharmaceutical and biotech companies access to the STAR program in a cost- and time-effective manner. "The STAR program is a one of a kind surveillance initiative profiling serious fungal infections, including Candida auris and Aspergillus, against common and experimental antifungals under development," said Dr. Mahmoud Ghannoum, Founder of NTS Ventures.
"The STAR surveillance program will provide valuable information regarding serious fungal infections and provide the medical community with up to date and pertinent information regarding antifungal agents," said Dr. Daniel Sahm, Chief Scientific Officer and VP of Global Microbiology Services at IHMA, Inc.
ABOUT NTS Ventures
NTS is based in Cleveland, OH and provides preclinical, clinical and translational services designed to bring antifungal, antibacterial and dermatology agents from discovery to market. NTS has the ability to support drug development in preclinical and clinical testing phases in order to satisfy FDA Investigational New Drug (IND) and New Drug Application (NDA) submissions. Over the past 25 years the NTS team has worked with a large range of entities including global Big Pharma, start up and growth stage biotech companies, full-spectrum CRO's as well as academic institutions.
For more information, please visit https://www.ntsventures.com.
IHMA is based in Schaumburg, IL USA and Monthey, Switzerland and has been a premier provider of antimicrobial drug development services over the past 25 years. Our laboratory facilities in both the US and Europe partner with clients around the world in the biotechnology, pharmaceutical, and diagnostic industries. IHMA is a leading, independent laboratory specializing in surveillance studies and clinical trials, key milestones along the continuum from drug development to commercialization. IHMA utilizes state of the art technology, leading to first-class testing and data as well as sound economic frameworks. IHMA’s services can be customized to best align with its clients’ unique testing needs. This ensures successful drug development, commercialization, and post-marketing pathways. For more information, visit the IHMA website at: www.ihma.com
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
AkzoNobel’s Q2 results show progress towards 15 by 20 strategy, with adjusted operating income up 36%, despite continued external headwinds24.7.2019 07:00:00 CEST | Press release
July 24, 2019 AkzoNobel’s Q2 results show progress towards 15 by 20 strategy, with adjusted operating income up 36%, despite continued external headwinds Akzo Nobel N.V. (AKZA; AKZOY) publishes results for second quarter 2019 • Adjusted operating income1 36% higher at €305 million (2018: €225 million) • ROS, excluding unallocated costs,2 increased to 13.7% (2018: 12.1%) • Focus on value over volume resulted in price/mix up 5% and 6% lower volumes • Transformation on track and delivered €43 million cost savings • Acquisition of Mapaero, announced July 18, 2019, further strengthens our aerospace coatings business Q2 2019: • Revenue was flat and up 1% in constant currencies, with positive price/mix of 5% and acquisitions contributing 1%, offset by 6% lower volumes • Adjusted operating income up 36% at €305 million (2018: €225 million, which included €20 million of one-off costs) driven by ongoing pricing initiatives and cost-saving programs; ROS at 12.4% (2018: 9.2%) • Operating income at
4th consecutive quarter of near double-digit growth in retail service revenues24.7.2019 07:00:00 CEST | Press release
Press release Embargo until July 24, 2019 at 7:00 am Regulated information Financial information for the second quarter of 2019 and first half of 2019 4th consecutive quarter of near double-digit growth in retail service revenues Mobile postpaid customer base grew 6.8% yoy on quarterly net-adds of 26k Convergence customer base increased 58.8% yoy on quarterly net-adds of 16k Revenues: +1.9% yoy for the quarter / Retail service revenues:+9.6% yoy for the quarter EBITDAaL +18.2% yoy for the quarter (H1’19 : +7.4% yoy, +4.2% excluding seasonality effect) Belgium Q2’19 operating highlights Bold challenger positioning is driving operating and financial performance. Orange Belgium has been drilling consistent messages around delivering better value proposition, simple tariffs (generous data and voice allowance), no bad surprises and no price increases. That bold positioning is being increasingly anchored in the consumers’ brand perception. Mobile postpaid continues its growth trajectory. The
Clariant AG: Clariant’s Board of Directors accepted resignation of CEO Ernesto Occhiello24.7.2019 07:00:00 CEST | Press release
Clariant’s Board of Directors accepted resignation of CEO Ernesto Occhiello Negotiations with SABIC concerning creation of Business Area High Performance Materials continue Muttenz, July 24, 2019– Clariant, a focused and innovative specialty chemical company, today announced that Ernesto Occhiello, Chief Executive Officer and Member of the Executive Committee, has decided to leave the company for personal reasons with immediate effect. The Board of Directors accepted his resignation yesterday. The Board of Directors asked Hariolf Kottmann, Chairman of the Board of Directors of Clariant, to assume his responsibilities in the interim as Executive Chairman until a successor is found. “We thank Ernesto Occhiello for his support of the company in a challenging phase and his contributions to strengthening the company’s position as a market leader in specialty chemicals during the past months,” said Hariolf Kottmann. Hariolf Kottmann added: “Clariant will continue to implement its strategy an
Standard & Poor’s has affirmed Arion Bank’s long term credit rating BBB+ but revised the outlook from stable to negative23.7.2019 20:32:00 CEST | Press release
Standard & Poor’s has affirmed Arion Bank’s long term credit rating BBB+ but revised the outlook from stable to negative. The Bank’s short term credit rating remains A-2. Main comments from Standard & Poor’s: The affirmation of the bank’s ratings reflects that Arion Bank maintains a solid market position in Iceland, with relatively advanced digitalized banking platforms while its exceptional capitalization counterbalances it’s geographic and loan book concentrations. Standard & Poor’s see Arion Bank as being well ahead of many other European banks in its preparation for technological disruption In a fiercely competitive environment, no longer supported by a strong economy, Icelandic banks' business prospects and earnings have become weaker. Furthermore, the role of pension funds in lending distorts Icelandic banks' competitive environment in terms of business generation and margins. Therefore it is seen as a negative trend for industry risk. Overall, economic risks for Icelandic banks
All Regulatory Clearances for Saxo Bank and BinckBank obtained to close the Offer23.7.2019 18:20:00 CEST | Press release
This is a joint press release by BinckBank N.V. (BinckBank), Star Bidco B.V. (the Offeror) and Saxo Bank A/S (Saxo Bank, pursuant to Section 4, paragraph 3 of the Dutch decree on public takeover bids (Besluit openbare biedingen Wft) in connection with the recommended public offer by the Offeror for all the issued and outstanding ordinary and priority shares in the capital of BinckBank (the Offer). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the Offer Memorandum dated 12 March 2019 (the Offer Memorandum). This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, the United States or Canada or in any other jurisdiction in which such release, publication or distribution would be unlawful. Terms not defined in this press release will have the meaning as set forth in the Offer Memorandum. All Regulatory Cleara
Golar LNG Partners LP Cash Distributions23.7.2019 18:13:00 CEST | Press release
Golar LNG Partners LP (“the Partnership”) (NASDAQ: GMLP) announced today that its board of directors has approved a quarterly cash distribution with respect to the quarter ended June 30, 2019 of $0.4042 per common and general partner unit. This cash distribution will be paid on August 14, 2019 to all common and general partner unitholders of record as of the close of business on August 7, 2019. A cash distribution of $0.546875 per Series A preferred unit (NASDAQ: GMLPP) for the period from May 15, 2019 through August 14, 2019 has also been declared. This will be payable on August 15, 2019 to all Series A preferred unitholders of record as at August 8, 2019. Golar LNG Partners LP Hamilton, Bermuda July 23, 2019 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act